Published in J Immunol on August 28, 2013
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog (2014) 1.14
STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res (2014) 1.04
Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol (2016) 0.98
Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc Natl Acad Sci U S A (2015) 0.97
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol (2016) 0.96
Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol (2015) 0.96
Designing DNA nanodevices for compatibility with the immune system of higher organisms. Nat Nanotechnol (2015) 0.92
Activation of the STING adaptor attenuates experimental autoimmune encephalitis. J Immunol (2014) 0.90
Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. Cancer Res (2015) 0.89
Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy. J Immunol (2015) 0.87
Innate immune signaling and regulation in cancer immunotherapy. Cell Res (2016) 0.86
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res (2016) 0.83
The host STING pathway at the interface of cancer and immunity. J Clin Invest (2016) 0.83
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res (2016) 0.82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
NET23/STING promotes chromatin compaction from the nuclear envelope. PLoS One (2014) 0.80
Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol (2014) 0.79
Apoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity. Immunol Rev (2016) 0.78
Metabolic control of tumour progression and antitumour immunity. Curr Opin Oncol (2014) 0.77
Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. Int J Radiat Oncol Biol Phys (2017) 0.76
Cutting Edge: Novel Tmem173 Allele Reveals Importance of STING N Terminus in Trafficking and Type I IFN Production. J Immunol (2015) 0.76
STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy? Expert Rev Clin Immunol (2014) 0.76
Virus Infections Incite Pain Hypersensitivity by Inducing Indoleamine 2,3 Dioxygenase. PLoS Pathog (2016) 0.76
Taking the STING out of TLR-driven autoimmune diseases: good, bad, or indifferent? J Leukoc Biol (2016) 0.75
Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity. Biomaterials (2016) 0.75
State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther (2016) 0.75
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int J Mol Sci (2017) 0.75
Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways. Trends Immunol (2017) 0.75
Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood (2017) 0.75
Rationale for stimulator of interferon genes-targeted cancer immunotherapy. Eur J Cancer (2017) 0.75
DNA methylation governs the dynamic regulation of inflammation by apoptotic cells during efferocytosis. Sci Rep (2017) 0.75
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 14.57
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature (2009) 9.74
IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol (2010) 8.97
Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42
HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science (2009) 6.59
STING is a direct innate immune sensor of cyclic di-GMP. Nature (2011) 6.44
The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol (2011) 5.34
The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun (2010) 3.89
Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med (2008) 3.74
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity (2012) 3.49
STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A (2012) 2.59
Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol (2005) 2.51
Structural mechanism of cytosolic DNA sensing by cGAS. Nature (2013) 2.50
On the role of IRF in host defense. J Interferon Cytokine Res (2002) 2.44
Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J Clin Invest (2007) 2.34
Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev (2001) 2.18
Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity (2012) 1.56
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.37
Physiologic control of IDO competence in splenic dendritic cells. J Immunol (2011) 1.29
The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol (2010) 1.26
STING-dependent signaling. Nat Immunol (2011) 1.08
Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J Immunol (2012) 1.06
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol (2012) 1.02
DNA-responsive inflammasomes and their regulators in autoimmunity. Clin Immunol (2011) 0.94
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature (2008) 10.73
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature (2009) 9.74
STING is a direct innate immune sensor of cyclic di-GMP. Nature (2011) 6.44
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Analysis of Pseudomonas aeruginosa diguanylate cyclases and phosphodiesterases reveals a role for bis-(3'-5')-cyclic-GMP in virulence. Proc Natl Acad Sci U S A (2006) 4.33
Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol (2002) 4.31
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun (2010) 3.89
Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity (2011) 3.74
A cyclic-di-GMP receptor required for bacterial exopolysaccharide production. Mol Microbiol (2007) 3.54
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity (2012) 3.49
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
The second messenger bis-(3'-5')-cyclic-GMP and its PilZ domain-containing receptor Alg44 are required for alginate biosynthesis in Pseudomonas aeruginosa. Mol Microbiol (2007) 3.11
The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J (2003) 3.09
The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep (2013) 3.08
A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med (2009) 2.92
Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell (2013) 2.90
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J Immunol (2007) 2.78
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol (2004) 2.77
Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59
STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A (2012) 2.59
VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell (2005) 2.55
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol (2003) 2.54
Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol (2008) 2.52
Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol (2005) 2.51
A FADD-dependent innate immune mechanism in mammalian cells. Nature (2004) 2.50
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med (2006) 2.44
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 2.44
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 2.30
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
NKG2D function protects the host from tumor initiation. J Exp Med (2005) 2.19
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell (2013) 2.18
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol (2005) 2.18
Control of formation and cellular detachment from Shewanella oneidensis MR-1 biofilms by cyclic di-GMP. J Bacteriol (2006) 2.15
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 2.14
Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol (2007) 2.13
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol (2004) 2.13
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer (2002) 2.10
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell (2004) 1.93
The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol (2007) 1.89
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83